References
- Tefferi A, Lasho TL, Abdel-Wahab O, . IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential trombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24:1302–1309.
- Thol F, Weissinger EM, Krauter J, . IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95:1668–1674.
- Mardis D, Ding L, Dooling DJ, . Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058–1066.
- Paschka P, Schlenk RF, Gaidzik VI, . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636–3643.
- Gross S, Cairns RA, Minden MR, . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339–344.
- Ward PS, Patel J, Wise DR, . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225–234.
- Tefferi A, Jimma T, Sulai NH, . IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26:475–480.
- Thol F, Damm F, Wagner K, . Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010;116:614–616.
- Green CL, Evans CM, Zhao L, . The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011;118:409–412.
- Chou WC, Peng KY, Lei WC, . Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia 2011;26:527–529.
- Jeziskova I, Razga F, Bajerova M, . IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leuk Lymphoma 2010;51:2285–2287.
- Dvorakova D, Racil Z, Jeziskova I, . Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am J Hematol 2010;85:926–929.
- Chiu RWK, Murphy MF, Fidler C, . Determination of RhD zygosity: comparison of a double amplification refractory mutation system approach and a multiplex real-time quantitative PCR approach. Clin Chem 2001;47:667–672.
- Dohner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
- Yen KE, Bittinger MA, Su SM, . Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010;29:6409–6417.